肝纤维化和肝硬化逆转的时代:现状与挑战

王冰琼; 孙亚朦; 尤红

doi:10.3969/j.issn.1001-5256.2019.04.001

肝纤维化和肝硬化逆转的时代:现状与挑战

DOI: 10.3969/j.issn.1001-5256.2019.04.001

首都医科大学附属北京友谊医院肝病中心国家消化系统疾病临床医学研究中心

详细信息

中图分类号: R575.2
计量
- 文章访问数: 519
- HTML全文浏览量: 49
- PDF下载量: 557
- 被引次数: 0
出版历程
- 收稿日期: 2019-01-12
- 出版日期: 2019-04-20

The era of the reversal of liver fibrosis and cirrhosis: Current status and challenges

Liver Research Center, Beijing Friendship Hospital, Capital Medical University & National Clinical Research Center for Digestive Diseases

摘要

摘要: 越来越多的临床研究表明,有效的病因治疗可以逆转肝纤维化/早期肝硬化。纤维化逆转的准确评估对于治疗决策及判断预后具有重要价值。然而目前肝纤维化及肝硬化逆转的组织学"金标准"仍待完善,肝纤维化逆转的无创评估仍有争议,能否改善临床硬终点尚需长期队列观察,同时抗纤维化新药的临床疗效尚有待进一步证实。
- 肝硬化 /
- 生物学标记 /
- 活组织检查 /
- 述评
Abstract: An increasing number of clinical studies have shown that effective etiological therapy might achieve the reversal of liver fibrosis/early cirrhosis. An accurate assessment of fibrosis reversal is of great importance for treatment decision-making and prognosis prediction. At present, the“gold standard”for the histological evaluation of liver fibrosis/cirrhosis reversal remains to be perfected, and there is still a controversy over the noninvasive assessment of fibrosis reversal. Long-term cohort studies are needed to observe whether it can improve clinical hard endpoint, and the clinical effect of new anti-fibrotic drugs needs to be further confirmed.
- liver cirrhosis /
- biological markers /
- biopsy /
- editorial

HTML全文

参考文献(37)

[1] SUN Y, ZHOU J, WANG L, et al. New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment[J]. Hepatology, 2017, 65 (5) :1438-1450.

[2]DUCHATELLE V, MARCELLIN P, GIOSTRA E, et al. Changes in liver fibrosis at the end of alpha interferon therapy and 6 to18 months later in patients with chronic hepatitis C:Quantitative assessment by a morphometric method[J]. J Hepatol, 1998, 29 (1) :20-28.

[3]GOODMAN ZD, STODDARD AM, BONKOVSKY HL, et al. Fibrosis progression in chronic hepatitis C:Morphometric image analysis in the HALT-C trial[J]. Hepatology, 2009, 50 (6) :1738-1749.

[4]ARIMA M, TERAO H, KASHIMA K, et al. Regression of liver fibrosis in cases of chronic liver disease type C:Quantitative evaluation by using computed image analysis[J]. Intern Med, 2004, 43 (10) :902-910.

[5]SUN Y, ZHOU J, WU X, et al. Quantitative assessment of liver fibrosis (qFibrosis) reveals precise outcomes in Ishak"stable"patients on anti-HBV therapy[J]. Sci Rep, 2018, 8 (1) :2989.

[6] WANLESS IR, NAKASHIMA E, SHERMAN M. Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis[J]. Arch Pathol Lab Med, 2000, 124 (11) :1599-1607.

[7]BEDOSSA P. Reversibility of hepatitis B virus cirrhosis after therapy:Who and why?[J]. Liver Int, 2015, 35 (Suppl 1) :78-81.

[8] CHON YE, PARK JY, MYOUNG SM, et al. Improvement of liver fibrosis after long-term antiviral therapy assessed by fibroscan in chronic hepatitis B patients with advanced fibrosis[J]. Am J Gastroenterol, 2017, 112 (6) :882-891.

[9]FACCIORUSSO A, DEL PRETE V, TURCO A, et al. Longterm liver stiffness assessment in hepatitis C virus patients undergoing antiviral therapy:Results from a 5-year cohort study[J]. J Gastroenterol Hepatol, 2018, 33 (4) :942-949.

[10]LIANG X, XIE Q, TAN D, et al. Interpretation of liver stiffness measurement-based approach for the monitoring of hepatitis B patients with antiviral therapy:A 2-year prospective study[J]. J Viral Hepat, 2018, 25 (3) :296-305.

[11]DONG XQ, WU Z, LI J, et al. Declining in liver stiffness cannot indicate fibrosis regression in patients with chronic hepatitis B:A 78-week prospective study[J]. J Gastroenterol Hepatol, 2018.[Epub ahead of print]

[12]IMAJO K, KESSOKU T, HONDA Y, et al. Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography[J]. Gastroenterology, 2016, 150 (3) :626-637.e7.

[13]TAPPER EB, LOOMBA R. Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD[J]. Nat Rev Gastroenterol Hepatol, 2018, 15 (5) :274-282.

[14]JAYAKUMAR S, MIDDLETON MS, LAWITZ EJ, et al. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis:Analysis of data from a phase II trial of selonsertib[J]. J Hepatol, 2018.[Epub ahead of print]

[15]VILAR-GOMEZ E, CHALASANI N. Non-invasive assessment of non-alcoholic fatty liver disease:Clinical prediction rules and blood-based biomarkers[J]. J Hepatol, 2018, 68 (2) :305-315.

[16]KIM BK, KIM DY, PARK JY, et al. Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients[J]. Liver Int, 2010, 30 (4) :546-553.

[17]LIN ZH, XIN YN, DONG QJ, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis:An updated meta-analysis[J]. Hepatology, 2011, 53 (3) :726-736.

[18]KIM WR, BERG T, ASSELAH T, et al. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients[J]. J Hepatol, 2016, 64 (4) :773-780.

[19]XU H, KONG W, LIU L, et al. Accuracy of M2BPGi, compared with Fibro Scan, in analysis of liver fibrosis in patients with hepatitis C[J]. BMC Gastroenterol, 2017, 17 (1) :62.

[20]ZOU X, ZHU MY, YU DM, et al. Serum WFA+-M2BP levels for evaluation of early stages of liver fibrosis in patients with chronic hepatitis B virus infection[J]. Liver Int, 2017, 37 (1) :35-44.

[21]SHIRABE K, BEKKI Y, GANTUMUR D, et al. Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis:More than a biomarker of liver fibrosis[J]. J Gastroenterol, 2018, 53 (7) :819-826.

[22]HUI CK, LEUNG N, SHEK WH, et al. Changes in liver histology as a"surrogate"end point of antiviral therapy for chronic HBV can predict progression to liver complications[J]. J Clin Gastroenterol, 2008, 42 (5) :533-538.

[23]MALLET V, GILGENKRANTZ H, SERPAGGI J, et al. Brief communication:The relationship of regression of cirrhosis to outcome in chronic hepatitis C[J]. Ann Intern Med, 2008, 149 (6) :399-403.

[24]PAPATHEODORIDIS GV, IDILMAN R, DALEKOS GN, et al.The risk of hepatocellular carcinoma decreases after the first 5years of entecavir or tenofovir in caucasians with chronic hepatitis B[J]. Hepatology, 2017, 66 (5) :1444-1453.

[25]KIM MN, KIM SU, KIM BK, et al. Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis[J]. Hepatology, 2015, 61 (6) :1851-1859.

[26]KIM BS, SEO YS, KIM YS, et al. Reduced risk of hepatocellular carcinoma by achieving a subcirrhotic liver stiffness through antiviral agents in hepatitis B virus-related advanced fibrosis or cirrhosis[J]. J Gastroenterol Hepatol, 2018, 33 (2) :503-510.

[27]WU S, KONG Y, PIAO H, et al. On-treatment changes of liver stiffness at week 26 could predict 2-year clinical outcomes in HBV-related compensated cirrhosis[J]. Liver Int, 2018, 38 (6) :1045-1054.

[28]SCHWABL P, HAMBRUCH E, SEELAND BA, et al. The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction[J]. J Hepatol, 2017, 66 (4) :724-733.

[29]RATZIU V, HARRISON SA, FRANCQUE S, et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptoralpha and-delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening[J]. Gastroenterology, 2016, 150 (5) :1147-1159, e5.

[30]NEUSCHWANDER-TETRI BA, LOOMBA R, SANYAL AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT) :A multicentre, randomised, placebo-controlled trial[J]. Lancet, 2015, 385 (9972) :956-965.

[31]IKENAGA N, PENG ZW, VAID KA, et al. Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal[J]. Gut, 2017, 66 (9) :1697-1708.

[32]HARRISON SA, ABDELMALEK MF, CALDWELL S, et al. Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis[J]. Gastroenterology, 2018, 155 (4) :1140-1153.

[33]FRIEDMAN SL, RATZIU V, HARRISON SA, et al. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis[J]. Hepatology, 2018, 67 (5) :1754-1767.

[34]HARRISON SA, MARRI SR, CHALASANI N, et al. Randomised clinical study:GR-MD-02, a galectin-3 inhibitor, vs.placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis[J]. Aliment Pharmacol Ther, 2016, 44 (11-12) :1183-1198.

[35]LOOMBA R, LAWITZ E, MANTRY PS, et al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis:A randomized, phase 2 trial[J]. Hepatology, 2017.[Epub ahead of print]

[36]MOHANTY A, TATE JP, GARCIA-TSAO G. Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis C-related compensated cirrhosis[J].Gastroenterology, 2016, 150 (2) :430-440. e1.

[37]KAMAL S, KHAN MA, SETH A, et al. Beneficial effects of statins on the rates of hepatic fibrosis, hepatic decompensation, and mortality in chronic liver disease:A systematic review and Meta-analysis[J]. Am J Gastroenterol, 2017, 112 (10) :1495-1505.

施引文献

资源附件(0)

访问统计